Search results
Results from the WOW.Com Content Network
Volume growth of Amgen's (AMGN) key drugs like Prolia, Kyprolis, Repatha and others and biosimilars portfolio is expected to have been partially offset by biosimilar/generic competition for mature ...
Shares of Amgen (NASDAQ: AMGN) are down by 6% in the last 30 days as I write this -- a larger-than-normal amount for a large pharma company's stock to fall, especially considering that the market ...
On June 17, 1983, Amgen went public, selling two million common shares and raising nearly $40 million. [10] [11] [12] That same year, after more than two years of work, an Amgen research team led by Fu-Kuen Lin had a breakthrough in finding and cloning the erythropoietin gene, a protein created in the kidney that stimulates red blood cell ...
Volume growth from Amgen's (AMGN) key drugs like Prolia, Xgeva, Repatha and others is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Here's where the business might go from here, and whether it's worth investing in Amgen today. ... In 2023, it brought in $7.4 billion in free cash and its dividend payout amounted to $4.6 billion.
Rank Year Purchaser Target Value (in billions USD) Value (adjusted for inflation) 1 2015 Pfizer: Allergan, plc: 160 206 In November 2015 Pfizer announced it would acquire Allergan, plc for $160 billion ($206 billion, adjusted for inflation).
Amgen's positive trial results update on its GLP-1 injectable for obesity, MariTide, sent its stock up more than 13% in trading Friday.CEO Bob Bradway shared a peek at phase II results of the ...
For premium support please call: 800-290-4726 more ways to reach us